🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

XTNT XTNT

Company Profile ↓
$0.32
-49.21% 1Y
Mkt Cap$44.81M
P/E10.67
P/B1.21
52W High$0.92
52W Low$0.31
Book Value$0.36
EPS (TTM)$0.03

Company Overview

XTNT (XTNT) is a publicly traded company listed on with a market capitalization of $44.81M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 15.5% CAGR over the past five years.

Reasonable Valuation

Trades at an undemanding P/E of 10.7.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $133.93M (+14.2% YoY); net profit $4.97M.
  • Trailing 12 Months Year-on-year growth — revenue +14.2%.
  • 5-Year Trend Long-term compounding — revenue CAGR 15.5%.

Growth & Price Performance

Compounded Sales Growth

5 Years:15.50%
1 Year:14.21%

Stock Price Performance

1 Year:-49.21%
6 Months:-46.67%
3 Months:-28.89%
1 Month:-3.03%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 2% of range
$0.31 $0.92
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)38.17 · Neutral
Price Performance
1M-3.03%
3M-28.89%
6M-46.67%
1Y-49.21%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 15.5% over 5 years.
  • Generates positive free cash flow.

CONS

  • Trading 65.2% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
10.67
Industry PE
-
Forward P/E est.
9.34
PEG Ratio
-
Book Value
$0.36
Price to Book
1.21
P/S
0.46
EV/EBITDA
4.61
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
15.50%
Profit 5Y
-
Revenue (YoY)
14.21%
Earnings (YoY)
-

Profitability & Returns

ROCE
11.26%
ROE
9.76%
ROA
5.28%
Profit Margin
3.71%
Op Margin
5.44%
Gross Margin
62.92%
EPS (Latest Qtr)
$-0.02
EPS (TTM)
$0.03

Balance Sheet & Liquidity

Debt/Equity
0.56
Quick Ratio
1.63
Current Ratio
2.65
Debt
$28.72M
Total Assets
$78.00M
Current Assets
$62.62M
Working Capital
$48.76M

Ownership

Promoter Holding
15.65%
Chg in Prom Hold
0.85%
FII / Inst Holding
56.94%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
$44.81M
Total Revenue (TTM)
$133.93M
EBITDA
$15.89M
Free Cash Flow
$10.16M
Operating Cash Flow
$12.55M
Shares Outstanding
140.04M
Gross Margin
62.92%
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2013Mar 2014Jun 2014Sep 2014Mar 2015Jun 2015Sep 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue --------------18.74M17.27M16.73M15.27M15.72M14.78M10.53M14.02M12.54M14.97M13.78M12.96M15.28M14.46M17.94M20.23M25.02M27.87M29.94M27.94M-32.90M35.41M33.26M32.36M20.88M
Cost of Revenue -----------------------------------12.66M11.13M11.26M14.60M8.91M
Gross Profit 4.61M5.50M5.59M5.44M6.03M6.52M11.66M14.10M14.70M15.98M14.91M13.53M11.37M12.23M12.47M11.52M10.81M9.91M10.41M9.61M6.55M9.25M8.09M9.52M7.19M7.56M8.37M7.90M10.54M12.46M15.33M17.30M18.58M16.31M-20.24M24.28M21.99M17.75M11.97M
Operating Expenses -----------------------------------19.18M19.66M19.45M18.70M14.89M
Operating Income -2.35M-1.19M-1.33M-1.25M-1.73M-1.38M-4.88M-2.36M-2.12M-1.90M-2.57M-6.35M-4.68M-1.66M-2.26M-1.44M-668.00K-563.00K-705.00K-1.36M-387.00K760.00K-5.00K-491.00K-1.45M-1.83M-1.30M-1.90M-1.58M-1.39M-3.38M-3.47M-2.95M-3.78M-1.06M4.62M2.54M-944.00K-2.92M
EBITDA -----------------------------------2.15M5.98M3.63M4.13M-1.93M
Interest Expense -----------------------------------1.04M1.00M904.00K718.00K599.00K
Pretax Income -----------------------------------33.00K3.81M1.56M1.60M-3.06M
Tax Provision ------------------------------------25.00K255.00K257.00K1.54M27.00K
Net Income -4.38M-4.14M-1.90M-1.17M-4.18M-2.90M-6.69M-5.60M-4.46M-4.90M-5.79M-9.69M-8.51M-5.25M-5.00M-3.15M-2.80M-1.94M-1.88M-2.49M-2.46M-1.36M-29.00K-733.00K-1.80M-2.21M-1.71M-2.35M-2.08M-2.19M9.23M-4.40M-3.86M-5.02M-58.00K3.55M1.31M57.00K-3.09M
Diluted EPS -0.85-0.77-0.35-0.19-0.62-0.41-0.64-0.47-0.37-0.40-3.87-6.43-5.62-0.70-0.38-0.24-0.21-0.15-0.14-0.19-0.19-0.100.00-0.01-0.02-0.03-0.02-0.03-0.02-0.020.07-0.03-0.03-0.04-0.000.020.010.00-0.02
R&D Expense 37.74K254.58K322.28K378.25K433.56K291.17K794.46K899.58K783.90K928.93K699.00K640.00K504.00K414.00K418.00K347.00K262.00K210.00K203.00K245.00K111.00K176.00K214.00K243.00K262.00K213.00K241.00K229.00K174.00K180.00K490.00K527.00K636.00K701.00K-443.00K566.00K634.00K-435.00K

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 15.42M30.15M32.98M33.07M35.33M59.35M90.00M82.61M72.20M64.68M53.34M55.26M57.97M91.30M117.27M133.93M
Cost of Revenue ------------25.83M35.84M49.05M49.65M
Gross Profit 12.05M21.04M22.64M18.89M22.30M39.08M62.29M50.10M43.49M42.52M34.39M32.49M32.14M55.47M68.22M84.27M
Operating Expenses ------------38.89M65.62M80.29M76.99M
Operating Income -8.61M-6.45M-4.94M-9.01M-6.26M-12.08M-7.55M-37.83M-60.08M-2.25M-751.00K-3.85M-6.75M-10.16M-12.07M7.28M
EBITDA -------------5.43M5.08M-7.88M15.89M
Interest Expense ------------1.69M2.94M4.16M3.67M
Pretax Income -------------8.42M-1.04M-16.26M7.00M
Tax Provision ------------69.00K-1.70M187.00K2.03M
Net Income -19.47M-3.01M-7.71M-12.69M-10.51M-2.17M-19.49M-52.41M-70.10M-8.22M-7.02M-4.85M-8.48M660.00K-16.45M4.97M
Diluted EPS -0.61-0.08-0.18-2.80-1.76-0.24-18.46-34.76-5.97-0.63-0.25-0.06-0.090.01-0.120.03
R&D Expense ---572.36K1.44M2.55M3.41M2.44M1.70M932.00K657.00K870.00K915.00K1.34M2.38M2.10M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -15.76M23.17M34.50M28.88M27.95M141.03M144.10M105.70M46.42M43.16M41.47M-60.23M92.61M93.84M94.14M
Current Assets -------------49.32M64.87M67.12M78.25M
Cash & Equivalents 54.16K327.48K751.11K4.93M3.05M4.47M6.37M2.58M2.86M6.80M5.24M2.34M-20.30M5.71M6.20M17.05M
Inventory -------------17.29M36.88M38.63M30.26M
Receivables -------------10.85M20.73M20.66M17.80M
Total Liabilities -16.38M17.67M30.26M32.72M35.73M132.15M151.17M164.40M90.19M87.36M26.95M-26.06M41.26M50.87M43.19M
Current Liabilities -14.18M10.94M8.69M9.65M8.48M21.47M31.12M25.82M12.05M9.39M25.65M-15.22M22.99M28.58M29.48M
Long Term Debt -2.19M6.64M14.48M16.39M20.87M44.70M119.22M67.11M77.94M76.24M--9.69M17.17M22.04M11.03M
Total Debt -------------17.07M23.56M35.14M28.72M
Total Equity 4.68M-619.24K5.50M4.23M-3.84M-7.77M8.88M-7.07M-58.70M-43.77M-44.20M14.51M-34.17M51.35M42.96M50.95M
Shares Outstanding -------------108.87M130.18M139.05M140.04M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -8.37M-7.36M-10.79M-4.89M-7.32M-9.10M-14.41M-543.00K1.21M-413.00K-731.00K--5.34M-9.52M-11.90M12.55M
Investing Cash Flow -816.37K-1.02M-1.84M-693.30K-298.35K-73.57M-5.82M-1.61M-367.00K-544.00K-1.30M--1.56M-24.78M-3.73M7.90M
Financing Cash Flow 9.46M8.80M16.80M3.71M9.04M84.57M16.43M2.43M3.10M-603.00K-861.00K-9.02M19.69M16.07M-9.57M
Capital Expenditure -783.05K-962.31K-1.83M------624.00K-879.00K-1.54M--1.76M-1.46M-4.11M-2.38M
Free Cash Flow -9.16M-8.32M-12.62M-----588.00K-1.29M-2.28M--7.11M-10.97M-16.01M10.16M
Net Change in Cash ------------2.12M-14.61M447.00K10.88M
Share Buybacks 726.71K---------------

Ratios (Annual)

Figures in %.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 78.2%69.8%68.7%57.1%63.1%65.9%69.2%60.6%60.2%65.7%64.5%58.8%55.4%60.8%58.2%62.9%
Operating Margin % -55.9%-21.4%-15.0%-27.2%-17.7%-20.4%-8.4%-45.8%-83.2%-3.5%-1.4%-7.0%-11.7%-11.1%-10.3%5.4%
Net Margin % -126.3%-10.0%-23.4%-38.4%-29.7%-3.7%-21.7%-63.4%-97.1%-12.7%-13.2%-8.8%-14.6%0.7%-14.0%3.7%
ROE % 3,143.8%-54.7%-182.3%330.4%135.2%-24.5%275.6%89.3%160.1%18.6%-48.4%--24.8%1.3%-38.3%9.8%
ROCE % -543.9%-52.7%-19.2%-46.9%-32.2%-10.1%-6.7%-47.4%-174.8%-6.7%-4.7%--15.0%-14.6%-18.5%11.3%

Shareholding Pattern

Insiders
15.65%
Institutions
56.94%
Public Float
67.51%

Top Institutional Holders

#Holder% HeldSharesValue
1 Nantahala Capital Management, LLC 48.75% 68.39M $26.26M
2 AWM Investment Company, Inc. 4.26% 5.98M $2.30M
3 Vanguard Capital Management LLC 1.44% 2.01M $773.61K
4 Renaissance Technologies, LLC 0.67% 935.12K $359.08K
5 Geode Capital Management, LLC 0.37% 517.13K $198.58K
6 Crescent Grove Advisors, Llc 0.29% 412.02K $158.22K
7 Nano Cap New Millennium Growth Fund L P 0.29% 400.00K $153.60K
8 Vanguard Fiduciary Trust Co 0.18% 257.99K $99.07K
9 Citadel Advisors Llc 0.14% 191.37K $73.48K
10 Acadian Asset Management. LLC 0.13% 180.30K $69.23K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for XTNT

Yahoo Finance ue, 11 Aug 2026

Xtant Medical Holdings Inc (XTNT) (Q2 2026) Earnings Call Highlights: Strategic Expansion Amid ...

Despite a challenging quarter with declining revenue and margins, Xtant is positioning for growth through the Dillon integration and new product launches targeting a $7.5 billion market.

Yahoo Finance ue, 04 Aug 2026

Xtant Medical to Participate in the Canaccord Genuity 46th Annual Growth Conference

Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced that Sean Browne, CEO, Scott Neils, CFO, and Mark Schallenberger, COO…

Yahoo Finance hu, 14 May 2026

Xtant Medical Holdings, Inc. Q1 2026 Earnings Call Summary

Moby summary of Xtant Medical Holdings, Inc.'s Q1 2026 earnings call

Yahoo Finance Wed, 13 May 2026

Xtant Medical Holdings Inc (XTNT) Q1 2026 Earnings Call Highlights: Navigating Challenges and ...

Xtant Medical Holdings Inc (XTNT) reports a revenue decline but strengthens its market position with strategic initiatives and product launches.

Yahoo Finance hu, 07 May 2026

Xtant Medical to Announce First Quarter 2026 Financial Results on May 13, 2026

Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced that it will release its financial results for the first quarter ende…

Yahoo Finance Wed, 06 May 2026

Xtant Medical Expands Trivium™ Portfolio with the Commercial Launch of Trivium™ Shaped

Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced the commercial launch of Trivium™ Shaped, an extension of its Trivium…

XTNT — Frequently Asked Questions

What is the current share price of XTNT?

As of 2026-09-16 18:39 PDT, XTNT trades at $0.32 on NASDAQ/NYSE. Its 52-week range is $0.31 to $0.92.

What is the market capitalisation of XTNT?

XTNT has a market capitalisation of $44.81M on NASDAQ/NYSE.

What is the P/E ratio of XTNT?

XTNT trades at a trailing price-to-earnings (P/E) ratio of 10.67. Its price-to-book (P/B) ratio is 1.21.

What is the return on equity (ROE) of XTNT?

XTNT has a return on equity (ROE) of 9.76%. Its return on capital employed (ROCE) is 11.26%.

Is XTNT a good stock to buy?

This page provides a data-driven analysis of XTNT, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space